GADRELON Trademark

Trademark Overview


On Monday, June 27, 2022, a trademark application was filed for GADRELON with the United States Patent and Trademark Office. The USPTO has given the GADRELON trademark a serial number of 97477638. The federal status of this trademark filing is ABANDONED - NO STATEMENT OF USE FILED as of Monday, November 4, 2024. This trademark is owned by Glaxo Group Limited. The GADRELON trademark is filed in the Pharmaceutical Products category with the following description:

Vaccines; Pharmaceutical preparations and substances for the treatment of damaged skin and tissue; Pharmaceutical preparations for the treatment of infectious diseases, pain, inflammation, obesity and cognitive disorders; Pharmaceutical preparations for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, oncological, hepatological, respiratory, neurological, gastrointestinal, dermatological, psychiatric and immune system related diseases and disorders
gadrelon

General Information


Serial Number97477638
Word MarkGADRELON
Filing DateMonday, June 27, 2022
Status606 - ABANDONED - NO STATEMENT OF USE FILED
Status DateMonday, November 4, 2024
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, January 31, 2023

Trademark Statements


Goods and ServicesVaccines; Pharmaceutical preparations and substances for the treatment of damaged skin and tissue; Pharmaceutical preparations for the treatment of infectious diseases, pain, inflammation, obesity and cognitive disorders; Pharmaceutical preparations for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, oncological, hepatological, respiratory, neurological, gastrointestinal, dermatological, psychiatric and immune system related diseases and disorders

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateThursday, July 14, 2022
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameGlaxo Group Limited
Party Type20 - Owner at Publication
Legal Entity Type99 - Other
AddressStevenage SG12NY
GB

Party NameGlaxo Group Limited
Party Type10 - Original Applicant
Legal Entity Type99 - Other
AddressBrentford, Middlesex TW89GS

Trademark Events


Event DateEvent Description
Thursday, June 30, 2022NEW APPLICATION ENTERED
Thursday, July 14, 2022NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Wednesday, November 9, 2022TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Wednesday, November 9, 2022ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Wednesday, November 9, 2022TEAS CHANGE OF CORRESPONDENCE RECEIVED
Tuesday, December 27, 2022ASSIGNED TO EXAMINER
Wednesday, December 28, 2022APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, January 11, 2023NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, January 31, 2023PUBLISHED FOR OPPOSITION
Tuesday, January 31, 2023OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, March 28, 2023NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, September 19, 2023SOU EXTENSION 1 GRANTED
Tuesday, September 19, 2023SOU TEAS EXTENSION RECEIVED
Tuesday, September 19, 2023SOU EXTENSION 1 FILED
Thursday, September 21, 2023NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, March 21, 2024SOU EXTENSION 2 FILED
Monday, November 4, 2024ABANDONMENT - NO USE STATEMENT FILED
Monday, November 4, 2024ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
Friday, March 22, 2024NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, March 21, 2024SOU TEAS EXTENSION RECEIVED
Thursday, March 21, 2024SOU EXTENSION 2 GRANTED